反応式
[CH:1]1([N:4]([CH2:18][C:19]2[S:23][C:22]([C:24](OCC)=[O:25])=[N:21][N:20]=2)[S:5]([C:8]2[C:13]([CH3:14])=[CH:12][C:11]([O:15][CH3:16])=[CH:10][C:9]=2[CH3:17])(=[O:7])=[O:6])[CH2:3][CH2:2]1.[N:29]1([CH2:34][CH2:35][CH:36]2[CH2:41][CH2:40][NH:39][CH2:38][CH2:37]2)[CH2:33][CH2:32][CH2:31][CH2:30]1.C[Al](C)C>ClCCCl>[NH3:4].[CH:1]1([N:4]([CH2:18][C:19]2[S:23][C:22]([C:24]([N:39]3[CH2:38][CH2:37][CH:36]([CH2:35][CH2:34][N:29]4[CH2:33][CH2:32][CH2:31][CH2:30]4)[CH2:41][CH2:40]3)=[O:25])=[N:21][N:20]=2)[S:5]([C:8]2[C:13]([CH3:14])=[CH:12][C:11]([O:15][CH3:16])=[CH:10][C:9]=2[CH3:17])(=[O:7])=[O:6])[CH2:3][CH2:2]1参加物
6
反応物 3
生成物 2
試薬・触媒・溶媒 1
実験手順
The title compound was prepared according to general procedure AT using ethyl 5-({cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino}methyl)-1,3,4-thiadiazole-2-carboxylate (30 mg, 0.07 mmol), 4-[2-(pyrrolidin-1-yl)ethyl]piperidine (29 mg, 0.16 mmol) and trimethylaluminium (2 M in toluene, 0.07 mL) in DCE (5 mL). The crude product was purified using FCC, eluting with 95:4.5:0.5 DCM:MeOH:NH3, to afford the title compound.
後処理
- customThe title compound was prepared
- customThe crude product was purified
- washeluting with 95:4.5:0.5 DCM
出典と根拠
- ORDレコード
- ord-94aee724d7084f98928d3daa8e337184
- 出典データセット
- uspto-grants-2014_01
- 特許番号
- US08623859B2
関連ノート
読み込み中…